TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition, Physiological Markers, Daily Function and Quality of Life in Stroke Patients With Cognitive Decline
Brief Summary: The purpose of this study is to determine the treatment effects of sequential combination of aerobic exercise and cognitive training on cognitive function, physiological markers, daily function, physical function, social participation and quality of life in stroke patients with cognitive decline. The investigators hypothesized that: (1) sequential training protocol can improve outcome measures compared to single mode of training; (2) these treatment effects will retain at 6-month follow-up.


Options:
A: Arm Label: Mentor; Type: EXPERIMENTAL; Interventions: Behavioral: Mentor | Arm Label: Traditional rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mentor | Intervention Type: BEHAVIORAL; Name: Mentor; Assigned to Arm(s): Mentor, Traditional rehabilitation
B: Arm Label: OPC-Stroke, Usual care; Type: EXPERIMENTAL; Interventions: Other: OPC-Stroke, Other: Usual care | Arm Label: Usual care; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: OPC-Stroke; Assigned to Arm(s): OPC-Stroke, Usual care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): OPC-Stroke, Usual care, Usual care
C: Arm Label: Cognitive training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Aerobic exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise training | Arm Label: Sequential training group; Type: EXPERIMENTAL; Interventions: Behavioral: Sequential combination of aerobic exercise and cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training group | Intervention Type: BEHAVIORAL; Name: Aerobic exercise training; Assigned to Arm(s): Aerobic exercise training group | Intervention Type: BEHAVIORAL; Name: Sequential combination of aerobic exercise and cognitive training; Assigned to Arm(s): Sequential training group
D: Arm Label: sequential training group (SEQ); Type: EXPERIMENTAL; Interventions: Behavioral: aerobic exercise training, Behavioral: cognitive training | Arm Label: control intervention group (CI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: control training | Intervention Type: BEHAVIORAL; Name: aerobic exercise training; Assigned to Arm(s): sequential training group (SEQ) | Intervention Type: BEHAVIORAL; Name: control training; Assigned to Arm(s): control intervention group (CI) | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): sequential training group (SEQ)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition, Physiological Markers, Daily Function and Quality of Life in Stroke Patients With Cognitive Decline
Brief Summary: The purpose of this study is to determine the treatment effects of sequential combination of aerobic exercise and cognitive training on cognitive function, physiological markers, daily function, physical function, social participation and quality of life in stroke patients with cognitive decline. The investigators hypothesized that: (1) sequential training protocol can improve outcome measures compared to single mode of training; (2) these treatment effects will retain at 6-month follow-up.


Options:
A: Arm Label: Cognitive training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Aerobic exercise training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise training | Arm Label: Sequential training group; Type: EXPERIMENTAL; Interventions: Behavioral: Sequential combination of aerobic exercise and cognitive training | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training group | Intervention Type: BEHAVIORAL; Name: Aerobic exercise training; Assigned to Arm(s): Aerobic exercise training group | Intervention Type: BEHAVIORAL; Name: Sequential combination of aerobic exercise and cognitive training; Assigned to Arm(s): Sequential training group
B: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy
C: Arm Label: Aerobic treadmill training; Type: EXPERIMENTAL; Interventions: Other: Aerobic treadmill training | Arm Label: Control (overground walking); Type: SHAM_COMPARATOR; Interventions: Other: Control (overground walking) | Intervention Type: OTHER; Name: Aerobic treadmill training; Assigned to Arm(s): Aerobic treadmill training | Intervention Type: OTHER; Name: Control (overground walking); Assigned to Arm(s): Control (overground walking)
D: Arm Label: m-health stroke rehabilitation; Type: N/A; Interventions: Behavioral: Multimodal Exercise Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Multimodal Exercise Rehabilitation Program; Assigned to Arm(s): m-health stroke rehabilitation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: iPhone App Compared to Standard RR-measurement - iPARR Trial
Brief Summary: In this Trial we compare a new application (App) running on an iPhone (Apple inc., Model 4S) to determine systolic blood pressure (RR) and compare it to conventional oscillometric measurements using an Omron HBP-1300-E Pro device. We will include 1000 participants and perform seven repetitive blood pressure measurements (3 iPhone, 4 Omron) in each person. Primary parameter will be the absolute difference (Delta) between the correlating blood pressure measurements in mmHg.


Options:
A: Arm Label: Salt substitute; Type: EXPERIMENTAL; Interventions: Other: Salt substitute | Intervention Type: OTHER; Name: Salt substitute; Assigned to Arm(s): Salt substitute
B: Arm Label: High risk management; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package | Arm Label: Salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Community based salt reduction program | Arm Label: high risk management and salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package, Behavioral: Community based salt reduction program | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: High-risk patient standardized management package; Assigned to Arm(s): High risk management, high risk management and salt reduction | Intervention Type: BEHAVIORAL; Name: Community based salt reduction program; Assigned to Arm(s): Salt reduction, high risk management and salt reduction
C: Arm Label: Blood pressure-measurement; Type: EXPERIMENTAL; Interventions: Device: cuff device (Omron HBP-1300-E Pro), Device: iPhone 4s | Intervention Type: DEVICE; Name: cuff device (Omron HBP-1300-E Pro); Assigned to Arm(s): Blood pressure-measurement | Intervention Type: DEVICE; Name: iPhone 4s; Assigned to Arm(s): Blood pressure-measurement
D: Arm Label: Normal Salt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regular Salt | Arm Label: Salt Substitute; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Salt Substitute | Intervention Type: DIETARY_SUPPLEMENT; Name: Regular Salt; Assigned to Arm(s): Normal Salt | Intervention Type: DIETARY_SUPPLEMENT; Name: Salt Substitute; Assigned to Arm(s): Salt Substitute

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Integrating Child and Adolescent Mental Health Into Primary Health Care and Traditional Healers' Practice: a Randomized Controlled Trial in Eastern Uganda
Brief Summary: This randomized controlled trial will compare the effect of a CAMH integration package on yield of CAMH cases compared to non-CAMH integrated sites. It will be conducted among nurses, midwives and clinical officers who provide PHC services to children and adolescents in 42 health centers; and eligible traditional healers.


Options:
A: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
B: Arm Label: CAMH training; Type: EXPERIMENTAL; Interventions: Other: CAMH training | Arm Label: No CAMH training; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CAMH training; Assigned to Arm(s): CAMH training
C: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
D: Arm Label: PRIME; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PRIME/mhGAP | Arm Label: PRIME+RESHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: RESHAPE, Behavioral: PRIME/mhGAP | Intervention Type: BEHAVIORAL; Name: RESHAPE; Assigned to Arm(s): PRIME+RESHAPE | Intervention Type: BEHAVIORAL; Name: PRIME/mhGAP; Assigned to Arm(s): PRIME, PRIME+RESHAPE

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Brief Summary: Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning. The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in three visits. At the first visit, subjects are screened for eligibility and enrolled. Baseline measures include rating scales and a frustrative computerized task. They will then wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study measures are repeated, vital signs and side effects monitored. Subjects will return for a third and final visit on day 21 to repeat the study measures performed during visit two.


Options:
A: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Balovaptan (RO5285119) 10 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Arm Label: Balovaptan (RO5285119) 4 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO5285119; Assigned to Arm(s): Balovaptan (RO5285119) 10 mg/d equivalent, Balovaptan (RO5285119) 4 mg/d equivalent

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Brief Summary: Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning. The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in three visits. At the first visit, subjects are screened for eligibility and enrolled. Baseline measures include rating scales and a frustrative computerized task. They will then wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study measures are repeated, vital signs and side effects monitored. Subjects will return for a third and final visit on day 21 to repeat the study measures performed during visit two.


Options:
A: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last
D: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
Brief Summary: Some individuals with autism spectrum disorders (ASD) also demonstrate irritability or aggression, which can interfere with functioning. The purpose of this pilot study is to test whether transdermal nicotine is effective for irritability and/or aggression in adults with ASD using a double-blind, placebo-controlled clinical trial. Subjects will participate in three visits. At the first visit, subjects are screened for eligibility and enrolled. Baseline measures include rating scales and a frustrative computerized task. They will then wear seven days of transdermal nicotine or placebo. Visit two is on day seven and the study measures are repeated, vital signs and side effects monitored. Subjects will return for a third and final visit on day 21 to repeat the study measures performed during visit two.


Options:
A: Arm Label: Trichuris Suis Ova (TSO); Type: EXPERIMENTAL; Interventions: Drug: Trichuris Suis Ova | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Trichuris Suis Ova | Intervention Type: DRUG; Name: Trichuris Suis Ova; Assigned to Arm(s): Placebo, Trichuris Suis Ova (TSO)
B: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last
C: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
D: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Brain Computer Interface and Brain-Controlled Stroke Rehabilitation Method Utilizing Electroencephalography in Hemiparetic and Hemiplegic Stroke Patients to Achieve Thought Control of Machines and a Better Understanding of Brain Function
Brief Summary: The ultimate goal of this project is to develop a functioning and clinically feasible method for restoring function to motor-impaired stroke survivors. This ultimate goal will be approached through two different means. The first method is to develop a functioning brain-computer interface that operates based on cortical activity ipsilateral to an intended movement on the motor-impaired side of the body. And secondly, to develop new methods of rehabilitation that involve stimulating peripheral muscles based upon cortical activity ipsilateral to intended movements. Finally, the study seeks to assess changes in functional connectivity as a result of using a BCI device.


Options:
A: Arm Label: Ankle-foot orthosis (AFO) Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Ankle-foot orthosis | Arm Label: Ness L300 Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Ness L300 | Intervention Type: DEVICE; Name: Ness L300; Assigned to Arm(s): Ness L300 Treatment Group | Intervention Type: DEVICE; Name: Ankle-foot orthosis; Assigned to Arm(s): Ankle-foot orthosis (AFO) Control Group
B: Arm Label: Device-assisted rehabilitation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation; Rehabilitation Robot | Intervention Type: DEVICE; Name: Electrical Stimulation; Rehabilitation Robot; Assigned to Arm(s): Device-assisted rehabilitation
C: Arm Label: IpsiHand; Type: EXPERIMENTAL; Interventions: Device: IpsiHand Device | Intervention Type: DEVICE; Name: IpsiHand Device; Assigned to Arm(s): IpsiHand
D: Arm Label: Ankle-Foot Orthosis (AFO); Type: ACTIVE_COMPARATOR; Interventions: Other: Ankle-Foot Orthosis (AFO) | Arm Label: WalkAide; Type: ACTIVE_COMPARATOR; Interventions: Device: WalkAide | Intervention Type: DEVICE; Name: WalkAide; Assigned to Arm(s): WalkAide | Intervention Type: OTHER; Name: Ankle-Foot Orthosis (AFO); Assigned to Arm(s): Ankle-Foot Orthosis (AFO)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Brief Summary: The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.


Options:
A: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
B: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding
Brief Summary: The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight infants.


Options:
A: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
B: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
C: Arm Label: Probiotics; Type: N/A; Interventions: N/A
D: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B